Form 8-K - Current report:
SEC Accession No. 0001193125-24-193404
Filing Date
2024-08-05
Accepted
2024-08-05 08:11:59
Documents
15
Period of Report
2024-08-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d833325d8k.htm   iXBRL 8-K 24902
2 EX-99.1 d833325dex991.htm EX-99.1 23377
6 GRAPHIC g833325g0805082225663.jpg GRAPHIC 2694
  Complete submission text file 0001193125-24-193404.txt   185642

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA annx-20240805.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20240805_lab.xml EX-101.LAB 18756
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20240805_pre.xml EX-101.PRE 11707
17 EXTRACTED XBRL INSTANCE DOCUMENT d833325d8k_htm.xml XML 3768
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 241173171
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)